- Report
- November 2023
- 171 Pages
Global
From €5283EUR$5,500USD£4,548GBP
- Report
- February 2024
- 125 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €2401EUR$2,500USD£2,067GBP
- Report
- March 2024
- 200 Pages
Global
From €3986EUR$4,150USD£3,432GBP
- Report
- January 2024
- 245 Pages
Global
€4798EUR$4,995USD£4,130GBP
- Report
- September 2023
- 120 Pages
North America
From €5715EUR$5,950USD£4,920GBP
- Report
- July 2019
- 280 Pages
Global
From €4321EUR$4,499USD£3,720GBP
- Report
- November 2020
- 260 Pages
Global
From €1321EUR$1,375USD£1,137GBP
€2641EUR$2,750USD£2,274GBP
- Report
- November 2018
- 147 Pages
Global
From €1321EUR$1,375USD£1,137GBP
€2641EUR$2,750USD£2,274GBP
- Report
- April 2023
- 120 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Report
- January 2022
- 121 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Report
- May 2022
- 74 Pages
North America
From €1441EUR$1,500USD£1,240GBP
- Report
- March 2022
- 71 Pages
North America
From €1441EUR$1,500USD£1,240GBP
- Report
- November 2021
- 600 Pages
Global
From €3842EUR$4,000USD£3,308GBP
The Abuse Deterrent market within the context of Analgesics is a growing sector of the pharmaceutical industry. Abuse Deterrent formulations are designed to reduce the potential for misuse and abuse of prescription medications. These formulations are designed to make the drug less attractive to abusers, such as by making it harder to crush, snort, or inject. Abuse Deterrent formulations are also designed to reduce the potential for accidental overdose.
The Abuse Deterrent market is driven by the need to reduce the misuse and abuse of prescription medications, as well as the need to reduce the potential for accidental overdose. This market is expected to continue to grow as more pharmaceutical companies develop Abuse Deterrent formulations.
Some companies in the Abuse Deterrent market include Purdue Pharma, Endo Pharmaceuticals, Teva Pharmaceuticals, and Johnson & Johnson. Show Less Read more